Screening Libraries
Cat. | Size | Price | Stock | |
P20230 | 1mg/well * 14 Compounds | Inquiry | In stock | Contact Us |
P20230 | 100uL/well (10mM solution) * 14 Compounds | Inquiry | In stock |
manager@chemfaces.com | |
Tel | (0086)-27-8423-7683 |
Shelf Life | (0086)-27-84254680 |
Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
Container | 96 Well Format Sample |
Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
Shelf Life | 24 months (2-8 °) |
Intended Use | For research use only. Not for human use. Not sell to patients |
1. The products in the ChemFaces screening libraries are all from plants. |
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
Catalog No. | Information |
CFN99272 | Quercetin Quercetin is one of the most prominent dietary antioxidants, it is claimed to exert beneficial health effects, this includes protection against various diseases such as osteoporosis, certain forms of cancer, pulmonary and cardiovascular diseases but also against aging. It is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively. It also attenuated the function VEGFR, androgen receptor and the expressions of NF-κB, IL Receptor, FAK, ERK,Nrf2. |
CFN99115 | 6,7-Dihydroxycoumarin 6,7-Dihydroxycoumarin(Esculetin) has various biological and pharmaceutical properties including anti-edema, anti-inflammatory, anti-tumour, hepatoprotective, anti-osteoarthritis and anti-rheumatoid arthritis effects. It inhibits lipoxygenases (LOs), p42/44 MAPK activation, PI3-kinase activation, as well as NF-kappaB and AP-1 activation, it exhibits competitive inhibition against the oxidation of 3-(3,4-dihydroxyphenyl)- alanine by mushroom, the IC50 value of is 43 microM. |
CFN99114 | Esculin Esculin has neuroprotective, anti-oxidative, and anti-apoptotic effects, it is a plant coumarin compound that occur naturally in dietary plants or when supplemented in the diet probably inhibit the survival of E. coli O157 in the gut. Esculin has protective effects on dopamine(DA)-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. Esculin has a protective effect on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice, it can inhibit the Toll-like receptor-2 (TLR2), Toll-like receptor-4 (TLR4), myeloid differentiation primary response gene-88 (MyD88), and nuclear factor-κB (NF-κB) p65 in LPS-induced ALI. |
CFN99113 | Fraxetin Fraxetin has dual-antioxidative ,hepatoprotective and antihyperglycemic functions, it shows potent protective effects against CCl4 induced oxidative stress and hepatic fibrosis, has a marked inhibitory effect on S.aureus proliferation. It increased the level of Nrf2/ARE, and HO-1, inhibit the formation of ROS, cytochrome c release, activation of caspase-3 and 9, and suppressed the up-regulation of Bax. |
CFN98850 | Quercitrin Quercitrin is an antibacterial agent and inhibits the oxidation of low-density lipoproteins and prevent an allergic reaction; quercitrin and DNJ in combination as a potent anticariogenic agent against S. mutans.Quercitrin has antioxidant, anti-inflammatory, anti-cancer, and anti-allergic activities. Quercitrin has antiproliferative and apoptotic effects on lung cancer cells and colon cancer cells by modulating the immune response; it promotes osteoblast differentiation in MC3T3-E1 cells and also inhibit osteoclastogenesis in RAW264.7 cells. |
CFN90193 | Gypenoside XVII Gypenoside XVII confers protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, inactivation of GSK-3β and activation of Nrf2/ARE/HO-1 pathways. Gypenoside XVII has protective effects to the cellular and rodent models of Alzheimer's disease by activating TFEB. |
CFN99509 | Sodium Aescinate Sodium aescinate has immunity enhancing,anti-inflammatory and antioxidant activities, may effectively control and improve wound healing in diabetic rats. It has obvious antiangiogenic effect, the initiation of angiogenesis and proliferation of endothelial cell are inhibited and the secretion of VEGF is also decreased. Sodium aescinate can protect the lung injury induced by intestinal ischemia/reperfusion (I/R), which may be mediated by inhibiting lipid peroxidation, upregulating Bcl-2 gene protein expression, improving the ratio of Bcl-2/ Bax to inhibit lung apoptosis.;it also can protect against liver injury induced by methyl parathion. |
CFN98333 | Leucoside Pure leucoside can be prepared by enzymatic partial hydrolysis of tea seed extract . |
CFN93368 | Escin IA Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression. |
CFN90934 | Escin IB Escin Ib inhibits gastric emptying, at least in part, mediated by capsaicin-sensitive sensory nerves, to stimulate the synthesis and/or release of dopamine, to act through central dopamine2 receptor, which in turn causes the release of PGs. |